EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial

Atul Verma iD, David E Haines, Lucas V Boersma iD, Nitesh Sood, Andrea Natale iD, Francis E Marchlinski iD, Hugh Calkins iD, Prashanthan Sanders iD, Douglas L Packer iD, Karl-Heinz Kuck iD, Gerhard Hindricks, Birce Onal iD und 4 weitere

Circulation · 09.05.2023 · 147 (19) · 1422-1432

DOI: 10.1161/circulationaha.123.063988 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Circulation, erschienen am 09.05.2023. Verfasst von Atul Verma und 15 weiteren Autor:innen. Beteiligte Einrichtung: McGill University Health Centre, Montreal, Canada (A.V.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Pulmonary Veins. Die Arbeit wurde bisher 634-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medtronic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pulsed field ablation uses electrical pulses to cause nonthermal irreversible electroporation and induce cardiac cell death. Pulsed field ablation may have effectiveness comparable to traditional catheter ablation while preventing thermally mediated complications.

Methods

The PULSED AF pivotal study (Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF) was a prospective, global, multicenter, nonrandomized, paired single-arm study in which patients with paroxysmal (n=150) or persistent (n=150) symptomatic atrial fibrillation (AF) refractory to class I or III antiarrhythmic drugs were treated with pulsed field ablation. All patients were monitored for 1 year using weekly and symptomatic transtelephonic monitoring; 3-, 6-, and 12-month ECGs; and 6- and 12-month 24-hour Holter monitoring. The primary effectiveness end point was freedom from a composite of acute procedural failure, arrhythmia recurrence, or antiarrhythmic escalation through 12 months, excluding a 3-month blanking period to allow recovery from the procedure. The primary safety end point was freedom from a composite of serious procedure- and device-related adverse events. Kaplan-Meier methods were used to evaluate the primary end points.

Results

Pulsed field ablation was shown to be effective at 1 year in 66.2% (95% CI, 57.9 to 73.2) of patients with paroxysmal AF and 55.1% (95% CI, 46.7 to 62.7) of patients with persistent AF. The primary safety end point occurred in 1 patient (0.7%; 95% CI, 0.1 to 4.6) in both the paroxysmal and persistent AF cohorts.

Conclusions

PULSED AF demonstrated a low rate of primary safety adverse events (0.7%) and provided effectiveness consistent with established ablation technologies using a novel irreversible electroporation energy to treat patients with AF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04198701.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationPulmonary VeinsHumansProspective StudiesTreatment OutcomeAnti-Arrhythmia AgentsElectrocardiographyRecurrence

Stichwörter der Autor:innen

atrial fibrillationcatheter ablationclinical trialelectroporationpulsed field ablation

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • McGill University Health Centre, Montreal, Canada (A.V.).
  • Beaumont Health, Royal Oak, MI (D.E.H.).
  • St. Antonius Hospital, Nieuwegein and Amsterdam UMC, the Netherlands (L.V.B.).
  • Southcoast Health Center, Fall River, MA (N.S.).
  • Texas Cardiac Arrhythmia Institute, Austin (A.N.).
  • Hospital of the University of Pennsylvania, Philadelphia (F.E.M.).

ORCID-Profile: Atul Verma, Lucas V Boersma, Andrea Natale, Francis E Marchlinski, Hugh Calkins, Prashanthan Sanders, Douglas L Packer, Karl-Heinz Kuck, Birce Onal

Förderung

  • Medtronic

Zitieren

APA

Verma, A., Haines, D. E., Boersma, L. V., Sood, N., Natale, A., Marchlinski, F. E., Calkins, H., Sanders, P., Packer, D. L., Kuck, K. H., Hindricks, G., Onal, B., Cerkvenik, J., Tada, H., DeLurgio, D. B., & PULSED AF Investigators (2023). Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. Circulation, 147(19), 1422-1432. https://doi.org/10.1161/circulationaha.123.063988

Vancouver

Verma A, Haines DE, Boersma LV, Sood N, Natale A, Marchlinski FE, et al. Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. Circulation. 2023;147(19):1422-1432. doi:10.1161/circulationaha.123.063988

BibTeX
@article{Verma2023,
  author = {Verma, Atul and Haines, David E and Boersma, Lucas V and Sood, Nitesh and Natale, Andrea and Marchlinski, Francis E and Calkins, Hugh and Sanders, Prashanthan and Packer, Douglas L and Kuck, Karl-Heinz and Hindricks, Gerhard and Onal, Birce and Cerkvenik, Jeffrey and Tada, Hiroshi and DeLurgio, David B and PULSED AF Investigators, PULSED AF Investigators},
  title = {Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial},
  journal = {Circulation},
  year = {2023},
  volume = {147},
  number = {19},
  pages = {1422--1432},
  doi = {10.1161/circulationaha.123.063988}
}
Kostenlos starten →